- Early detection of DPN, even in the absence of clinical symptoms and signs
- Help with confirmation or rule-out of DPN and quantification of severity
- Monitoring changes in DPN over time and in response to treatment
NeuroMetrix (NURO) stock is rising in mid-morning trading on Tuesday after the company announced the commercial launch of its diabetes test in Mexico.
Stocks with insider trader activity include CMPR, AER and NURO
Stocks with insider trader activity include SKT, HEB and NURO